Cognitive ⏱ Half-life: ~10-20 minutes (estimated) Preclinical

Nesfatin-1

Nesfatin-1 (NUCB2-derived Satiety Peptide)

Updated March 30, 2026

Evidence at a Glance

Regulatory statusPreclinical
Endogenous NUCB2-derived satiety peptide; no interventional human trials or approvals, studied only as a research target.
Human evidenceNone
Animal evidenceModerate

Nesfatin-1 suppresses feeding and affects glucose handling in rodents, but there are no controlled trials of administering it to humans; human data are limited to observational biomarker correlations.

What the research does not support

  • It has no approved therapeutic use and no human trials as an administered drug.
  • It is not a proven weight-loss treatment; obese humans appear to show nesfatin resistance.
  • Its appetite and glucose effects come from animal models, not from human dosing studies.
Half-Life
~10-20 minutes (estimated)
Purity
≥95%
Mol. Weight
9,716 Da
Form
Lyophilized powder

What is Nesfatin-1?

Nesfatin-1 was discovered in 2006 as a novel anorexigenic peptide, generated from the cleavage of nucleobindin-2 (NUCB2). Its ability to reduce food intake independently of leptin makes it a particularly interesting target for obesity research, since leptin resistance is a hallmark of most human obesity.

Dosage Information (Research Use)

Research doses: 5-25 pmol ICV in rodent studies. No standardized human dosing. Peripheral administration less effective due to limited BBB penetration. Research compound only.

Reconstitution & Handling

Reconstitute in sterile saline or PBS.

Half-Life & Pharmacokinetics

~10-20 minutes (estimated)

Reported Observations in Literature

Reduced food intake (intended effect). May produce mild anxiety at higher doses. Limited human safety data available.

Key Research References

  • Oh-I S et al. “Identification of nesfatin-1 as a satiety molecule in the hypothalamus.” Nature. 2006;443:709-12

How Nesfatin-1 Works

Nesfatin-1 is an anorexigenic peptide that reduces food intake independently of leptin signaling. It acts on oxytocin neurons in the hypothalamic paraventricular nucleus and melanocortin pathways. Uniquely, it suppresses appetite in leptin-resistant models, suggesting a parallel satiety pathway that may remain functional in obesity.

Research Applications

🔬 Obesity and metabolic syndrome
🔬 Type 2 diabetes
🔬 Eating disorders and appetite control

Research Findings

ICV injection of nesfatin-1 reduces food intake in a dose-dependent manner. Obese subjects have altered nesfatin-1 levels. The peptide also shows anxiogenic and stress-response properties through CRH pathway interaction. Active research into peripherally administered analogs for obesity treatment.

Dosage & Administration

Research doses: 5-25 pmol ICV in rodent studies. No standardized human dosing. Peripheral administration less effective due to limited BBB penetration. Research compound only.

Safety & Side Effects

Reduced food intake (intended effect). May produce mild anxiety at higher doses. Limited human safety data available.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Molecular Weight 9,716 Da
Half-Life ~10-20 minutes (estimated)
Purity ≥95%
Form Lyophilized powder
Storage Lyophilized: -20°C.

Key Research References

  • Oh-I S et al. "Identification of nesfatin-1 as a satiety molecule in the hypothalamus." Nature. 2006;443:709-12

Related Peptides

View all →
Dihexa
Cognitive
Angiotensin IV analog reported to be 10 million times more potent than BDNF for synaptogenesis in animal models.
View Profile → Buy Now
P21
Cognitive
CNTF-derived tetrapeptide researched for neurogenesis, cognitive enhancement, and neurodegenerative disease models.
View Profile →
Orexin-A
Cognitive
Neuropeptide critical for wakefulness, appetite regulation, and energy homeostasis with therapeutic implications for narcolepsy.
View Profile →